The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
FOLFOX4 (12 cycles) versus sequential dose-dense FOLFOX7 (6 cycles) followed by FOLFIRI (6 cycles) in patients with initially resectable metastatic colorectal cancer: A GERCOR randomized phase III study (MIROX).
Mohamed Hebbar
No relevant relationships to disclose
Benoist Chibaudel
No relevant relationships to disclose
Thierry Andre
Honoraria - Sanofi
Laurent Mineur
No relevant relationships to disclose
Denis Smith
No relevant relationships to disclose
Christophe Louvet
No relevant relationships to disclose
Jean Luc Dutel
No relevant relationships to disclose
Marc Ychou
No relevant relationships to disclose
Jean-Louis Legoux
No relevant relationships to disclose
May Mabro
No relevant relationships to disclose
Dominique Auby
No relevant relationships to disclose
David Brusquant
No relevant relationships to disclose
Ahmed Khalil
No relevant relationships to disclose
Stephanie Truant
No relevant relationships to disclose
Alexandra Hadengue
No relevant relationships to disclose
Franck Bonnetain
No relevant relationships to disclose
Francois-Rene Pruvot
No relevant relationships to disclose
Cecile Dalban
No relevant relationships to disclose
Aimery De Gramont
No relevant relationships to disclose